TEINYO 3D Cervical Rehabilitation Robot

The TEINYO 3D Cervical Rehabilitation Robot represents a precision-engineered approach to cervical spine treatment, combining advanced force-control technology with intelligent rehabilitation protocols. Developed by TEINYO under the HRG (Harbin Institute of Technology Robot Group) technology platform, this system received NMPA certification in 2019, becoming one of the company’s flagship medical-grade products.

Product Overview

Designed for clinical rehabilitation environments, the 3D Cervical Rehabilitation Robot addresses cervical spondylosis and related neck disorders through automated, precisely controlled traction therapy. The system fills a domestic market gap identified by HRG in intelligent cervical rehabilitation equipment.

The development team invested one year specifically optimizing the force-control mechanism to achieve clinical-grade precision, resulting in a system capable of delivering therapeutic traction with exceptional accuracy and patient safety.

Key Features

TEINYO’s 3D Cervical Rehabilitation Robot’s 0.001-second force feedback response enables traction adjustments precise to 50 grams, supporting individualized treatment protocols.

• Millisecond Response Control: Traction feedback response time reduced to 0.001 seconds, enabling real-time adjustment during treatment
• Precision Force Application: Traction force accuracy to 50 grams, allowing fine-tuned therapeutic protocols for individual patient needs
• 3D Spatial Positioning: Multi-axis movement capability for full cervical spine treatment angles
• Intelligent Protocol Management: Automated rehabilitation programs based on patient condition assessment
• Safety Monitoring: Continuous force and position feedback prevents excessive stress on cervical structures

Technical Specifications

At ±50g force precision with 0.001-second response, this NMPA-certified (2019) system delivers therapeutic traction across all cervical spine levels via multi-axis movement.

Clinical Applications

The 3D Cervical Rehabilitation Robot supports treatment protocols for:

• Cervical spondylosis (degenerative disc disease)
• Cervical disc herniation
• Cervical radiculopathy
• Post-surgical cervical rehabilitation
• Chronic neck pain management
• Cervical muscle strain recovery

The precision force control enables clinicians to implement graduated traction protocols, starting with minimal force and progressively adjusting based on patient tolerance and therapeutic response.

Regulatory Status

The NMPA (formerly CFDA) certification positions this system for deployment in Chinese healthcare facilities including rehabilitation centers, hospitals, and specialized orthopedic clinics.

Technology Background

Development of the 3D Cervical Rehabilitation Robot drew upon HRG’s broader robotics capabilities and the HIT Medical Robot Laboratory’s research in rehabilitation engineering. The force-control technology represents a significant technical achievement, requiring extensive calibration to achieve the sub-gram precision levels necessary for safe cervical manipulation.

The system emerged from TEINYO’s 2016 development of 12 neural and orthopedic rehabilitation robot prototypes, with the cervical rehabilitation robot receiving focused development attention leading to its 2019 regulatory clearance.

Frequently Asked Questions

What conditions can the TEINYO 3D Cervical Rehabilitation Robot treat?

The system is designed for cervical spine rehabilitation including cervical spondylosis, disc herniation, radiculopathy, and chronic neck pain. Treatment protocols can be customized based on individual patient conditions and therapeutic goals.

How precise is the traction force control?

The system achieves force precision to 50 grams with response times of 0.001 seconds, enabling real-time adjustment during treatment. This level of precision allows clinicians to implement graduated, patient-specific traction protocols.

Is this product available outside China?

Currently, the 3D Cervical Rehabilitation Robot has NMPA certification for the Chinese market only. CE Mark and FDA clearance have not been pursued at this time.